contentSlug

type

ContentSlug_ContentQuery

slug

ContentPageContentQuery

content

trendingContent

query ContentSlug_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  tags {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  pageUrl
  alternatePageUrls: translations {
    __typename
    pageUrl
    lang
  }
  imgUrl
  description
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    id
    type
    title
    isPremium
    lang
    htmlBody
    summary
    companies {
      forum {
        latestPosts {
          ...ForumPosts
        }
      }
      name
      id
      viewerIsFollowing
      pageUrl
      defaultInstrument {
        isin
        id
        marketOpen
        marketClose
        marketplace {
          region
        }
        returns {
          total
        }
      }
    }
    tags {
      viewerIsFollowing
      id
      name
      pageUrl
    }
    createdAt
    ... on Video {
      liveTime
    }
    ... on Webcast {
      liveTime
    }
    slug
    ... on CompanyReport {
      reportUrl
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
  }
  ...TrendingContent_1jQ2Cn
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    name
    pageUrl
    defaultInstrument {
      priceData {
        tradeCurrency
      }
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
    id
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}

fragment TrendingContent_1jQ2Cn on Query {
  trendingContent(type: ARTICLE) {
    __typename
    id
    title
    lang
    pageUrl
    createdAt
    type
    imgUrl
    companies {
      squareLogoUrl
      name
      id
    }
    authors {
      __typename
      imgUrl
      id
    }
    publishers {
      imgUrl
    }
  }
}


curasight-q3-confirmed-the-company-is-on-track-from-a-medical-advancement-perspective

__typename

title

isPremium

lang

htmlBody

summary

companies

createdAt

publishers

authors

reactionGroups

pageUrl

translations

imgUrl

description

Equity Research Analyst

Henrik Ekman

CEO, Sweden

Claus Thestrup

Curasight är verksamt inom läkemedelsbranschen. Bolaget är specialiserat inom utveckling av teknologiska produkter. Produktportföljen har sitt huvudsakliga fokus inom utvecklingen av innovativa teknologier för diagnostik och behandling av cancer baserat på målstyrd PET-avbildning och radionuklidterapi. Verksamheten drivs med störst närvaro inom Skandinavien. Curasight har sitt huvudkontor i Köpenhamn.

Curasight

Curasight: Q3 confirmed - the company is on track from a medical advancement perspective.

Curasight: Q3 confirmed - the company is on track from a medical advancement perspective
Danish based biotech company Curasight released their 3rd quarter report last week which confirmed the company is on track from a medical advancement perspective as the company continues to make progress with its so called&nbsp;theranostic concept to combine diagnose and treatment of various forms of cancer. Still in their developing phase, Curasight reported zero revenue and a loss before tax of DKK 8,5 million and a loss of DKK 25,3 million for the first three quarters of 2023 as the company develops its pipeline of uTRACE and uTREAT product candidates for diagnosing and treating different forms of cancer types. Cash position remains strong with a cash position of DKK 27,7 million.
Investors has grown accustomed to witnessing Curasight publish encouraging new preclinical or clinical data to support an ongoing expansion of new types of cancer forms to be diagnosed and treated. Recently, the latest example was the announcement of positive preclinical data of uTREAT for non-small cell lung cancer. What has become more interesting, however, is the announcement of partner deals that validates both uTREAT and uTRACE as concepts &ndash; but also supports the company&rsquo;s funding situation. To illustrate, the share price of Curasight doubled in the weeks after the first &ndash; and so far only - of such announcements were made in the beginning of May of 2023, when Curasight entered a partnership arrangement with Curium to accelerate Curasight&rsquo;s development of uTRACE for prostate cancer. Since then, Curasight has continued to develop its pipeline, but no new partnerships have been announced, and although the Curasight share price is up more than 60 percent this year making it one of the best biotech investments, investors have seen the share price drop 35 percent from its peak in May when news of the deal was released. 
Investors eager to learn more about Curasight and its theranostic concept, as well as hearing more of the prospect and potential for new partnership deals can join the HCA event on Wednesday, November 29th where CEO Ulrich Krasilnikoff and CSO and co-founder Andreas Kj&aelig;r will present the 3rd quarter report and take questions. Please sign up here: <a href="https://www.inderes.dk/videos/curasight-praesentation-af-q3-2023" target="_blank" rel="noopener">Q3 event Curasight</a>
Disclaimer: HC Andersen Capital receives payment from Curasight for a Digital IR/Corporate Visibility subscription agreement. /Claus Thestrup 8:30 AM 27-11-2023.